Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study

被引:0
作者
U Haug
S Hundt
H Brenner
机构
[1] German Cancer Research Center,Division of Clinical Epidemiology and Aging Research
来源
British Journal of Cancer | 2008年 / 99卷
关键词
faecal tumour M2 pyruvate kinase; colorectal adenomas; screening; stool testing;
D O I
暂无
中图分类号
学科分类号
摘要
The measurement of faecal tumour M2 pyruvate kinase (tumour M2 PK) has been proposed as a novel approach for early detection of colorectal cancer (CRC). However, as regards the potential of the test to detect precursors to CRC, an issue that is highly relevant to estimate its use in reducing CRC incidence and mortality, the available evidence is scant and controversial. The aim of our study was to determine the performance characteristics of the tumour M2 PK test with respect to colorectal adenomas in the target population of screening. Among 1082 participants of screening colonoscopy in Germany, of whom 30% had any adenoma and 10% had an advanced adenoma, the median (interquartile range) tumour M2 PK level in the whole study population was 1.3 U ml−1 (0.3–3.3). At a cutoff value of 4 U ml−1, sensitivity was 22 and 23% for detection of advanced and other adenomas, respectively, whereas specificity was 82%. The area under the receiver-operating characteristics curve (95% confidence interval) was 0.54 (0.51–0.58) and 0.56 (0.52–0.59) for advanced and other adenomas, respectively. In conclusion, the tumour M2 PK test has only very limited potential to distinguish between people bearing precursors to CRC and people with no finding at colonoscopy.
引用
收藏
页码:133 / 135
页数:2
相关论文
共 57 条
  • [1] Barclay RL(2006)Colonoscopic withdrawal times and adenoma detection during screening colonoscopy N Engl J Med 355 2533-2541
  • [2] Vicari JJ(2004)Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer Br J Cancer 91 980-984
  • [3] Doughty AS(2006)Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting Clin Chem 52 782-784
  • [4] Johanson JF(2007)Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults Br J Cancer 96 1329-1334
  • [5] Greenlaw RL(2008) colorectal cancer patients Colorectal Dis 10 244-248
  • [6] Hardt PD(2002)Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention Br J Nutr 87 23-S29
  • [7] Mazurek S(2007)Pyruvate kinase type M2: a crossroad in the tumor metabolome Eur J Gastroenterol Hepatol 19 878-882
  • [8] Toepler M(2006)Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer Int J Cancer 119 2651-2656
  • [9] Schlierbach P(2006)Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia World J Gastroenterol 12 7007-7011
  • [10] Bretzel RG(2005)Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK Dtsch Med Wochenschr 130 872-877